GPCR Structure Therapeutics Inc. - American Depositary Shares
NASDAQ · Pharmaceuticals · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 6, 2026
$27.67
· of 52w range
· above low
· to high
$25.5952w low
$94.9052w high
Market Cap (MRQ)
$5.91B
P/E
-34.6
EPS
$-0.80
your badges
52W Range
$26–$95
Analyst Rating
BUY
Price Target
$106
P/E
-34.6
ROE
-12.3%
Net Profit Margin
·
Your badge strip is empty — pin a metric anywhere on this page.
GPCR Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$27.67
Market Cap (MRQ)
$5.91B
P/E
-34.6
EPS
$-0.80
ROE
-12.3%
52W Range
$26–$95
GPCR Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
EPS$-0.802022-12-31 → 2025-12-31
Free Cash Flow$-226M2023-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | GPCR | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | -34.65Y avg ≈-57.3 | ≈-57.3 | · | · | |
| P/B (MRQ) | 4.45Y avg ≈9.2 | ≈9.2 | 5.9 | Overvalued | |
| Price / FCF (TTM) | -26.35Y avg ≈-58.2 | ≈-58.2 | · | · | |
| Price / Cash Flow (TTM) | -26.85Y avg ≈-59.3 | ≈-59.3 | · | · | |
| Price / Tangible Book | 3.95Y avg ≈9.2 | ≈9.2 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | GPCR | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| ROA | -11.3%5Y avg ≈-20.0% | ≈-20.0% | -6.0% | Weak | |
| ROE | -12.3%5Y avg ≈-18.0% | ≈-18.0% | -12.6% | In line | |
| ROIC | -11.7%5Y avg ≈-17.6% | ≈-17.6% | -8.2% | Below avg |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | GPCR | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 20.85Y avg ≈22.9 | ≈22.9 | 3.4 | Strong liquidity | |
| Quick Ratio | 22.95Y avg ≈22.1 | ≈22.1 | 2.7 | Strong liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-152.9%
Next Report
Nov 04, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 4, 2026 | $-0.49 | $-0.41 | -20.8% |
| March 31, 2026 | May 6, 2026 | $-0.35 | $-0.35 | 1.2% |
| Dec. 31, 2025 | $-1.22 | $-0.47 | -157.1% | |
| Sept. 30, 2025 | $-1.11 | $-0.36 | -209.7% | |
| June 30, 2025 | $-1.08 | $-0.28 | -283.9% | |
| March 31, 2025 | $-0.81 | $-0.23 | -246.9% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| R&D Expense | $225M | $109M | $70M | $36M | |
| SG&A Expense | $62M | $49M | $33M | $16M | |
| Operating Expenses | $177M | $158M | $103M | $53M | |
| Operating Income | $-177M | $-158M | $-103M | $-53M | |
| Pretax Income | $-141M | $-122M | $-89M | $-51M | |
| Income Tax | $515.0K | $310.0K | $236.0K | $17.0K | |
| Net Income | $-141M | $-123M | $-90M | $-51M | |
| EPS (Basic) | $-0.80 | $-0.78 | $-0.81 | $-5.51 | |
| EPS (Diluted) | $-0.80 | $-0.78 | $-0.81 | $-5.51 | |
| Shares (Basic) | 177,596,000 | 157,922,000 | 110,198,000 | 9,584,000 | |
| Shares (Diluted) | 177,596,000 | 157,922,000 | 110,198,000 | 9,584,000 | |
| EBITDA | $-177M | $-158M | $-103M | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Cash & Equivalents | $800M | $170M | $130M | $26M | |
| Short-term Investments | $647M | $714M | $338M | $65M | |
| Prepaid Expense | $24M | $8M | $6M | $2M | |
| Current Assets | $1.57B | $891M | $474M | $93M | |
| PP&E (Net) | $7M | $3M | $3M | $1M | |
| PP&E (Gross) | $10M | $5M | $4M | $1M | |
| Accum. Depreciation | $3M | $2M | $644.0K | $349.0K | |
| Other Non-current Assets | $717.0K | $5M | $45.0K | $3M | |
| Total Assets | $1.58B | $903M | $482M | $98M | |
| Accounts Payable | $14M | $8M | $5M | $6M | |
| Current Liabilities | $63M | $36M | $25M | $13M | |
| Capital Leases | $4M | $2M | $4M | · | |
| Other Non-current Liabilities | $647.0K | $302.0K | $298.0K | · | |
| Total Liabilities | $68M | $38M | $29M | $13M | |
| Common Stock | $21.0K | $17.0K | $14.0K | $1.0K | |
| Paid-in Capital | $1.99B | $1.19B | $659M | $2M | |
| Retained Earnings | $-470M | $-329M | $-207M | $-117M | |
| AOCI | $1M | $914.0K | $521.0K | $-110.0K | |
| Stockholders' Equity | $1.52B | $865M | $453M | $-115M | |
| Liabilities + Equity | $1.58B | $903M | $482M | $98M | |
| Shares Outstanding | 212,513,000 | 171,860,000 | 139,220,000 | 10,527,000 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Stock-based Comp | $29M | $19M | $8M | $3M | |
| Operating Cash Flow | $-222M | $-117M | $-79M | $-46M | |
| CapEx | $4M | $1M | $2M | $155.0K | |
| Investing Cash Flow | $90M | $-359M | $-268M | $-62M | |
| Stock Issued | · | $515M | · | · | |
| Net Stock Activity | · | $515M | · | · | |
| Financing Cash Flow | $763M | $515M | $452M | $29M | |
| Net Change in Cash | $630M | $40M | $104M | $-79M | |
| Taxes Paid | $634.0K | $370.0K | $12.0K | · | |
| Free Cash Flow | $-226M | $-118M | $-82M | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| ROA | -11.3% | -17.7% | -30.9% | · | |
| ROE | -12.3% | -13.9% | -27.8% | · | |
| ROIC | -11.7% | -18.3% | -22.8% | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Current Ratio | 24.8 | 24.7 | 19.1 | · | |
| Quick Ratio | 22.9 | 24.5 | 18.9 | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Book Value / Share | $7.14 | $5.03 | $3.25 | · | |
| Cash Flow / Share | $-1.25 | $-0.74 | $-0.72 | · | |
| Cash / Share | $3.76 | $0.99 | $0.93 | · | |
| EPS (TTM) | $-0.80 | $-0.78 | $-0.81 | $-5.51 |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Net Income TTM | $-141M | $-123M | $-90M | $-51M | |
| Market Cap | $14.78B | $4.66B | $5.67B | · | |
| P/E | -86.9 | -34.8 | -50.3 | · | |
| P/B | 9.7 | 5.4 | 12.5 | · | |
| P / Tangible Book | 9.7 | 5.4 | 12.5 | · | |
| P / Cash Flow | -66.5 | -40.0 | -71.4 | · | |
| P / FCF | -65.5 | -39.5 | -69.5 | · | |
| Earnings Yield | -1.1% | -2.9% | -2.0% | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $100M | $67M | $69M | $59M | $55M | $43M | $33M | $33M | $22M | $21M | $18M | $19M | $13M | $8M | $9M | $10M | |
| SG&A Expense | $19M | $23M | $18M | $15M | $16M | $13M | $14M | $13M | $11M | $11M | $9M | $7M | $7M | $5M | $4M | $4M | |
| Operating Expenses | $119M | $89M | $-24M | $74M | $70M | $56M | $47M | $46M | $33M | $32M | $26M | $26M | $20M | $13M | $13M | $14M | |
| Operating Income | $-119M | $-89M | $24M | $-74M | $-70M | $-56M | $-47M | $-46M | $-33M | $-32M | $-26M | $-26M | $-20M | $-13M | $-13M | $-14M | |
| Pretax Income | $-106M | $-76M | $33M | $-66M | $-62M | $-47M | $-36M | $-34M | $-26M | $-26M | $-23M | $-23M | $-18M | $-12M | $-12M | $-14M | |
| Income Tax | $234.0K | $190.0K | $170.0K | $108.0K | $139.0K | $98.0K | $136.0K | $92.0K | $53.0K | $29.0K | $405.0K | $118.0K | $25.0K | $-180.0K | $73.0K | $64.0K | |
| Net Income | $-106M | $-76M | $33M | $-66M | $-62M | $-47M | $-36M | $-34M | $-26M | $-26M | $-24M | $-23M | $-18M | $-12M | $-12M | $-14M | |
| EPS (Basic) | $-0.49 | $-0.35 | $0.20 | $-0.37 | $-0.36 | $-0.27 | $-0.21 | $-0.20 | $-0.18 | $-0.19 | $-0.21 | $-0.20 | $-0.25 | $-1.16 | $-1.27 | $-1.64 | |
| EPS (Diluted) | $-0.49 | $-0.35 | $0.20 | $-0.37 | $-0.36 | $-0.27 | $-0.21 | $-0.20 | $-0.18 | $-0.19 | $-0.21 | $-0.20 | $-0.25 | $-1.16 | $-1.27 | $-1.64 | |
| Shares (Basic) | 217,957,000 | 217,326,000 | · | 175,469,000 | 172,647,000 | 172,051,000 | · | 171,630,000 | 148,239,000 | 139,710,000 | 114,948,000 | 114,759,000 | 71,655,000 | · | 9,780,000 | 9,435,000 | |
| Shares (Diluted) | 217,957,000 | 217,326,000 | · | 175,469,000 | 172,647,000 | 172,051,000 | · | 171,630,000 | 148,239,000 | 139,710,000 | 114,948,000 | 114,759,000 | 71,655,000 | · | 9,780,000 | 9,435,000 | |
| EBITDA | $-119M | $-89M | · | $-74M | $-70M | $-56M | · | $-46M | $-33M | $-32M | $-26M | $-26M | $-20M | · | · | · |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $273M | $316M | $800M | $103M | $147M | $152M | $170M | $172M | $382M | $98M | $51M | $41M | $126M | $26M | · | · | |
| Short-term Investments | $1.07B | $1.14B | $647M | $696M | $639M | $685M | $714M | $743M | $545M | $339M | $155M | $184M | $114M | $65M | · | · | |
| Prepaid Expense | $29M | $32M | $24M | $15M | $13M | $13M | $8M | $8M | $11M | $13M | $5M | $4M | $5M | $2M | · | · | |
| Current Assets | $1.37B | $1.49B | $1.57B | $814M | $799M | $850M | $891M | $924M | $938M | $449M | $210M | $228M | $246M | $93M | · | · | |
| PP&E (Net) | $6M | $6M | $7M | $5M | $3M | $4M | $3M | $4M | $3M | $3M | $2M | $1M | $961.0K | $1M | · | · | |
| PP&E (Gross) | · | · | $10M | · | · | · | $5M | $5M | $4M | $4M | $3M | $2M | $1M | $1M | · | · | |
| Accum. Depreciation | · | · | $3M | · | · | · | $2M | $1M | $1M | $866.0K | $572.0K | $493.0K | $419.0K | $349.0K | · | · | |
| Other Non-current Assets | $41M | $6M | $717.0K | $7M | $6M | $6M | $5M | $2M | $2M | $47.0K | $350.0K | $38.0K | $59.0K | $3M | · | · | |
| Total Assets | $1.43B | $1.51B | $1.58B | $832M | $816M | $867M | $903M | $933M | $947M | $457M | $216M | $229M | $247M | $98M | · | · | |
| Accounts Payable | $11M | $8M | $14M | $18M | $9M | $9M | $8M | $8M | $2M | $7M | $3M | $6M | $5M | $6M | · | · | |
| Current Liabilities | $66M | $57M | $63M | $58M | $39M | $36M | $36M | $33M | $23M | $24M | $20M | $15M | $11M | $13M | · | · | |
| Capital Leases | $4M | $3M | $4M | $4M | $5M | $5M | $2M | $3M | $3M | $4M | $3M | · | · | · | · | · | |
| Other Non-current Liabilities | $1M | $863.0K | $647.0K | $325.0K | $317.0K | $308.0K | $302.0K | $309.0K | $293.0K | $296.0K | $281.0K | · | · | · | · | · | |
| Total Liabilities | $71M | $61M | $68M | $62M | $44M | $42M | $38M | $36M | $26M | $27M | $23M | $15M | $11M | $13M | · | · | |
| Common Stock | $21.0K | $21.0K | $21.0K | $18.0K | $17.0K | $17.0K | $17.0K | $17.0K | $17.0K | $14.0K | · | · | $11.0K | $1.0K | · | · | |
| Paid-in Capital | $2.01B | $2.00B | $1.99B | $1.27B | $1.21B | $1.20B | $1.19B | $1.19B | $1.18B | $663M | $375M | $373M | $371M | $2M | · | · | |
| Retained Earnings | $-652M | $-546M | $-470M | $-503M | $-438M | $-376M | $-329M | $-293M | $-259M | $-233M | $-182M | $-158M | $-135M | $-117M | · | · | |
| AOCI | $-3M | $-2M | $1M | $825.0K | $362.0K | $815.0K | $914.0K | $3M | $-487.0K | $-90.0K | $-310.0K | $-390.0K | $147.0K | $-110.0K | · | · | |
| Stockholders' Equity | $1.35B | $1.45B | $1.52B | $770M | $772M | $825M | $865M | $897M | $921M | $430M | $193M | $214M | $236M | $-115M | · | · | |
| Liabilities + Equity | $1.43B | $1.51B | $1.58B | $832M | $816M | $867M | $903M | $933M | $947M | $457M | $216M | $229M | $247M | $98M | · | · | |
| Shares Outstanding | 213,655,000 | 213,208,000 | 212,513,000 | 182,033,000 | 172,700,000 | 172,610,000 | 171,860,000 | 171,762,000 | 171,589,000 | 139,855,000 | · | · | 114,730,000 | 10,527,000 | · | · |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $13M | $12M | $8M | $7M | $8M | $6M | $6M | $6M | $4M | $3M | $2M | $2M | $3M | $623.0K | $628.0K | $643.0K | |
| Operating Cash Flow | $-120M | $15M | $-64M | $-51M | $-55M | $-52M | $-36M | $-20M | $-26M | $-34M | $-21M | $-17M | $-20M | $-12M | $-10M | $-10M | |
| CapEx | $-42.0K | $1M | $1M | $2M | $232.0K | $314.0K | $16.0K | $685.0K | $427.0K | $162.0K | $820.0K | · | · | $71.0K | $72.0K | $-53.0K | |
| Investing Cash Flow | $74M | $-497M | $56M | $-49M | $49M | $34M | $33M | $-189M | $-205M | $1M | $30M | $-69M | $-49M | $10M | $-17M | $-16M | |
| Stock Issued | · | · | · | · | · | · | · | $0 | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $2M | $-2M | $705M | $56M | $517.0K | $809.0K | $615.0K | $-757.0K | $515M | $702.0K | $473.0K | $-297.0K | $170M | $-316.0K | $-259.0K | $31M | |
| Net Change in Cash | $-44M | $-483M | $697M | $-44M | $-5M | $-17M | $-3M | $-209M | $284M | $-32M | $10M | $-86M | $100M | $-2M | $-27M | $5M | |
| Free Cash Flow | · | $14M | · | · | · | $-53M | · | · | · | $-34M | · | · | · | · | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -9.5% | -6.4% | · | -7.4% | -7.0% | -7.1% | · | -5.9% | -4.4% | -7.4% | -22.1% | · | -14.5% | · | · | · | |
| ROE | -10.0% | -6.7% | · | -7.9% | -7.3% | -7.5% | · | -6.2% | -4.6% | -7.8% | -24.7% | · | -15.2% | · | · | · | |
| ROIC | -8.8% | -6.2% | · | -9.6% | -9.2% | -6.8% | · | -5.1% | -3.6% | -7.5% | -13.8% | -12.2% | -8.3% | · | · | · |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 20.8 | 26.2 | · | 14.2 | 20.5 | 23.3 | · | 27.6 | 41.4 | 19.1 | 10.5 | 15.2 | 22.4 | · | · | · | |
| Quick Ratio | 20.3 | 25.6 | · | 13.9 | 20.1 | 22.9 | · | 27.4 | 40.9 | 18.5 | 10.2 | 15.0 | 21.9 | · | · | · |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $6.34 | $6.79 | · | $4.23 | $4.47 | $4.78 | · | $5.22 | $5.37 | $3.07 | · | · | $2.06 | · | · | · | |
| Cash Flow / Share | · | $0.07 | · | · | · | $-0.30 | · | · | · | $-0.24 | · | · | $-0.28 | · | · | · | |
| Cash / Share | $1.28 | $1.48 | · | $0.57 | $0.85 | $0.88 | · | $1.00 | $2.22 | $0.70 | · | · | $1.10 | · | · | · | |
| EPS (TTM) | $-1.01 | $-0.88 | · | $-1.21 | $-1.04 | $-0.86 | · | $-0.72 | $-0.73 | $-0.75 | $-1.82 | $-2.88 | $-4.32 | · | · | · |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-215M | $-170M | · | $-211M | $-179M | $-143M | · | $-111M | $-100M | $-98M | $-77M | $-66M | $-56M | · | · | · | |
| Market Cap | $11.47B | $10.28B | · | $5.10B | $3.58B | $2.99B | · | $7.54B | $6.74B | $5.99B | · | · | $2.73B | · | · | · | |
| P/E | -53.1 | -54.8 | · | -23.1 | -19.9 | -20.1 | · | -61.0 | -53.8 | -57.1 | -27.7 | -14.4 | -5.5 | · | · | · | |
| P/B | 8.5 | 7.1 | · | 6.6 | 4.6 | 3.6 | · | 8.4 | 7.3 | 13.9 | · | · | 11.5 | · | · | · | |
| P / Tangible Book | 8.5 | 7.1 | · | 6.6 | 4.6 | 3.6 | · | 8.4 | 7.3 | 13.9 | · | · | 11.5 | · | · | · | |
| P / Cash Flow | · | 674.6 | · | · | · | -57.2 | · | · | · | -175.9 | · | · | -134.4 | · | · | · | |
| Earnings Yield | -1.9% | -1.8% | · | -4.3% | -5.0% | -5.0% | · | -1.6% | -1.9% | -1.8% | -3.6% | -6.9% | -18.2% | · | · | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Net Income | $-141M | $-123M | $-90M | $-51M |
| Diluted EPS | $-0.80 | $-0.78 | $-0.81 | $-5.51 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Current Ratio | 24.8 | 24.7 | 19.1 | · |
| Quick Ratio | 22.9 | 24.5 | 18.9 | · |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-226M | $-118M | $-82M | · |
Institutional owners (13F) 204 filers · $3.6B total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
204
Value held
$3.6B
New positions
31
Exited positions
28
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 31 (-8 vs prior Q) | 28 (-10 vs prior Q) | 75 (+4 vs prior Q) | 55 (-11 vs prior Q) | -4.4M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| FMR LLC | $419,179,123 | 7,810,306 | 11.69% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $396,054,169 | 7,379,433 | 11.05% | Shares |
| Avoro Capital Advisors LLC | $351,836,637 | 6,555,555 | 9.81% | Shares |
| JANUS HENDERSON GROUP PLC | $258,260,143 | 5,354,981 | 7.20% | Shares |
| Deep Track Capital, LP | $254,399,664 | 4,740,072 | 7.10% | Shares |
| BVF INC/IL | $180,697,390 | 3,366,823 | 5.04% | Shares |
| MORGAN STANLEY | $150,632,372 | 2,806,640 | 4.20% | Shares |
| ORBIMED ADVISORS LLC | $118,578,498 | 2,209,400 | 3.31% | Shares |
| PRINCIPAL FINANCIAL GROUP INC | $94,070,254 | 1,752,753 | 2.62% | Shares |
| AMERICAN CENTURY COMPANIES INC | $90,282,956 | 1,682,179 | 2.52% | Shares |
| RTW INVESTMENTS, LP | $86,274,901 | 1,607,507 | 2.41% | Shares |
| Driehaus Capital Management LLC | $83,361,264 | 1,553,219 | 2.33% | Shares |
| BAKER BROS. ADVISORS LP | $76,883,831 | 1,432,529 | 2.14% | Shares |
| Casdin Capital, LLC | $63,062,250 | 1,175,000 | 1.76% | Shares |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $58,285,620 | 1,086,000 | 1.63% | Shares |
| CAPITOLIS LIQUID GLOBAL MARKETS LLC | $55,875,837 | 1,041,100 | 1.56% | Shares |
| Siren, L.L.C. | $46,852,139 | 872,967 | 1.31% | Shares |
| Pacific Heights Asset Management LLC | $42,936,000 | 800,000 | 1.20% | Shares |
| Rock Springs Capital Management LP | $34,365,813 | 640,317 | 0.96% | Shares |
| Aberdeen Group plc | $34,344,238 | 639,915 | 0.96% | Shares |
| FRANKLIN RESOURCES INC | $31,066,308 | 578,839 | 0.87% | Shares |
| BANK OF AMERICA CORP /DE/ | $30,238,858 | 563,422 | 0.84% | Shares |
| ALLIANCEBERNSTEIN L.P. | $29,484,326 | 611,708 | 0.82% | Shares |
| BlackRock, Inc. | $27,433,368 | 511,149 | 0.77% | Shares |
| Logos Global Management LP | $26,835,000 | 500,000 | 0.75% | Shares |
| Parkman Healthcare Partners LLC | $26,065,426 | 485,661 | 0.73% | Shares |
| Davern Capital Partners, LP | $23,939,987 | 446,059 | 0.67% | Shares |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $22,476,996 | 418,800 | 0.63% | Shares |
| UBS Group AG | $20,340,179 | 378,986 | 0.57% | Shares |
| DEUTSCHE BANK AG\ | $17,811,302 | 331,867 | 0.50% | Shares |
| NEXTBio Capital Management LP | $16,771,660 | 312,496 | 0.47% | Shares |
| Catalio Capital Management, LP | $14,842,438 | 276,550 | 0.41% | Shares |
| MARSHALL WACE, LLP | $14,361,663 | 267,592 | 0.40% | Shares |
| HSG Holding Ltd | $14,279,548 | 266,062 | 0.40% | Shares |
| SEB Asset Management AB | $13,151,433 | 245,043 | 0.37% | Shares |
| GOLDMAN SACHS GROUP INC | $13,030,539 | 242,790 | 0.36% | Shares |
| AMERIPRISE FINANCIAL INC | $12,371,685 | 230,514 | 0.35% | Shares |
| NATIONAL BANK OF CANADA /FI/ | $11,581,986 | 215,800 | 0.32% | Shares |
| TWO SIGMA INVESTMENTS, LP | $10,957,053 | 204,156 | 0.31% | Shares |
| Eversept Partners, LP | $10,535,528 | 196,302 | 0.29% | Shares |
| Schonfeld Strategic Advisors LLC | $10,234,062 | 190,685 | 0.29% | Shares |
| Woodline Partners LP | $8,254,875 | 153,808 | 0.23% | Shares |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $8,218,000 | 153,119 | 0.23% | Shares |
| ArrowMark Colorado Holdings LLC | $8,081,575 | 150,579 | 0.23% | Shares |
| Susquehanna Portfolio Strategies, LLC | $7,994,039 | 148,948 | 0.22% | Shares |
| CenterBook Partners LP | $7,944,770 | 148,030 | 0.22% | Shares |
| Rhenman & Partners Asset Management AB | $7,787,517 | 145,100 | 0.22% | Shares |
| GOLDMAN SACHS GROUP INC | $7,782,150 | 145,000 | 0.22% | Call option |
| B Group, Inc. | $7,513,800 | 140,000 | 0.21% | Shares |
| HighVista Strategies LLC | $7,019,177 | 130,784 | 0.20% | Shares |
Company insiders 19 insiders · 10 officers · 8 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Raymond C Stevens | CHIEF EXECUTIVE OFFICER | March 19, 2026 A | 1,401,593 | 0 | 0 | $0 |
| Jun Yoon | CHIEF FINANCIAL OFFICER | March 19, 2026 A | 1,401,656 | 0 | 0 | $0 |
| Matthew Lang | COO & GC | April 15, 2026 A | 184,614 | 0 | 0 | $0 |
| Crespo Blas Coll | CHIEF MEDICAL OFFICER | Sept. 21, 2026 S | 258,228 | 0 | 1 | $-144,889 |
| Xichen Lin | CHIEF SCIENTIFIC OFFICER | Sept. 1, 2026 S | 228,960 | 0 | 11 | $-1,472,329 |
| John Joseph Berrios | Chief Commercial Officer | Aug. 6, 2026 A | 140,766 | 0 | 0 | $0 |
| Yingli Ma | CHIEF TECHNOLOGY OFFICER | March 19, 2026 A | 139,917 | 0 | 0 | $0 |
| Ashley Hall | Chief Development Officer | March 19, 2026 A | 155,187 | 0 | 0 | $0 |
| Mark Allen Bach | CHIEF MEDICAL OFFICER | March 15, 2024 A | 26,235 | 0 | 0 | $0 |
| Melita Sun Jung | Chief Business Officer | Feb. 7, 2023 P | · | 0 | 0 | $0 |
| Joanne Waldstreicher | Director | June 17, 2026 A | · | 0 | 0 | $0 |
| Angus C. Russell | Director | June 17, 2026 A | · | 0 | 0 | $0 |
| Sharon Tetlow | Director | June 17, 2026 A | · | 0 | 0 | $0 |
| Daniel G Welch | Director | June 17, 2026 A | 123,508 | 0 | 0 | $0 |
| Eric Dobmeier | Director | June 17, 2026 A | · | 0 | 0 | $0 |
| Ted W Love | Director | June 17, 2026 A | · | 0 | 0 | $0 |
| Ramy Farid | Director | Feb. 7, 2023 P | 3,260,495 | 0 | 0 | $0 |
| FMR LLC | 10% owner | July 22, 2026 S | 4,769,404 | 0 | 22 | $-7,057,088 |
| FIL Ltd | · | Feb. 7, 2023 C | 624,239 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 4 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
GPCR Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 23 analysts
BUY
Median target
$101.00
+265.0%
8 34.8%
Strong Buy
13 56.5%
Buy
2 8.7%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
15 analysts · 2026-10-02Mean target $105.78 +282.3%
← Below all targets
Current price $27.67
Low$70.00
Mean$105.78
High$145.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| GPCR | $14.78B | -86.9 | · | · | -12.3% | · |
| AMRX | · | 57.3 | 8.1% | 2.4% | -80.0% | 36.9% |
| HRMY | $2.16B | 13.8 | 21.5% | 18.3% | 19.3% | 77.2% |
| PBH | $3.33B | 15.2 | -4.3% | 17.5% | 10.2% | 54.7% |
| TRLV | · | · | -0.45% | -10.3% | -10.4% | 60.2% |
| TRVI | $1.61B | -39.1 | · | · | -22.4% | · |
| NUVB | $3.03B | -14.9 | 699.0% | -325.3% | -60.3% | · |
| SEPN | $1.25B | -25.3 | 4174.5% | -106.4% | -12.9% | · |
| ANIP | $1.78B | 23.8 | 43.8% | 8.9% | 16.6% | · |
| LLY | · | 46.8 | 44.7% | 31.7% | 101.2% | · |
Latest News Recent headlines mentioning this company
Structure Therapeutics (GPCR) Is A Hidden Biotech Multibagger Stock To Buy Now
Yahoo Finance · 3 months ago
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position
Nasdaq · 4 months, 3 weeks ago
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges
Nasdaq · 6 months, 1 week ago
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 6, 2026